000043462 000__ 00901nam\a2200361\i\4500
000043462 001__ 43462
000043462 003__ SzGeWIPO
000043462 005__ 20230504171858.0
000043462 006__ m\\\\eo\\d\\\\\\\\
000043462 007__ cr bn |||m|||a
000043462 008__ 210504s2021\\\\enk\\\\\o\\\\\000\0\eng\d
000043462 022__ $$aOnline: 1747-1540
000043462 0247_ $$a10.1093/jiplp/jpab001$$2doi
000043462 035__ $$a(OCoLC)1255904365
000043462 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000043462 041__ $$aeng
000043462 24504 $$aThe CJEU abolishes Neurim and SPCs for new therapeutic indications.
000043462 264_1 $$a[Oxford, England] :$$bOxford University Press (OUP),$$c2021
000043462 300__ $$a1 online resource (pages 94-97)
000043462 337__ $$acomputer$$2rdamedia
000043462 4901_ $$aJournal Of Intellectual Property Law & Practice,$$x1747-1540 ;$$v16, 2 2021
000043462 542__ $$fhttps://academic.oup.com/jiplp/article/16/2/94/6166297
000043462 588__ $$aCrossref
000043462 590__ $$aPublished online: 10-Mar-21
000043462 650_0 $$aIntellectual property.
000043462 7001_ $$aZemła-Pacud, Żaneta,$$eauthor.
000043462 7731_ $$tJournal of Intellectual Property Law & Practice$$wjiplp
000043462 830_0 $$aJournal Of Intellectual Property Law & Practice ;$$v16, 2 2021.
000043462 85641 $$uhttps://doi.org/10.1093/jiplp/jpab001$$yOnline version
000043462 904__ $$aArticle
000043462 980__ $$aJIPLP